TuHURA Biosciences (HURA) Non-Current Assets (2015 - 2026)
TuHURA Biosciences' (HURA) quarterly Non-Current Assets came in at $22.7 million in Q1 2026, up 7152.7% year-on-year from $313297.0 in Q1 2025, and little changed quarter-over-quarter from $22.7 million in Q4 2025.
TuHURA Biosciences (HURA) Non-Current Assets (2015 - 2026) Analysis & Trends
TuHURA Biosciences' Non-Current Assets history runs 12 years deep, the most recent figure standing at $22.7 million for Q1 2026.
- On a quarterly basis, Non-Current Assets rose 7152.7% year-over-year to $22.7 million in Q1 2026; TTM through Mar 2026 was $89.7 million, a 4385.15% increase from a year earlier, with the FY2025 full-year figure at $22.7 million, up 6280.11% from the prior year.
- Non-Current Assets steadied at $22.7 million in Q1 2026 per HURA's latest filing, from $22.7 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $22.7 million in Q4 2025 and bottomed at $202990.0 in Q4 2023.
- The 5-year median for Non-Current Assets is $724000.0 (2023), against an average of $6.2 million.
- Across the five-year window, Non-Current Assets slumped 86.27% in 2023 and surged 7152.7% in 2026, its largest moves.
- Year by year, Non-Current Assets stood at $739000.0 in 2022, then sank by 72.53% to $202990.0 in 2023, then jumped by 75.52% to $356295.0 in 2024, then soared by 6280.11% to $22.7 million in 2025, then slipped by 0.04% to $22.7 million in 2026.
- Per Business Quant, the three latest HURA Non-Current Assets figures stand at $22.7 million (Q1 2026), $22.7 million (Q4 2025), and $22.2 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 21.65 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | 5.83 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 30.30 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 1.95 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 14.75 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 22.66 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | 289.41 Mn |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 1.96 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 285.82 Mn |
| 10 | TuHURA Biosciences | 132.62 Mn | 132.62 Mn | - | 22.72 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 22.72 Mn |
| Dec 31, 2025 | 22.73 Mn |
| Sep 30, 2025 | 22.19 Mn |
| Jun 30, 2025 | 22.08 Mn |
| Mar 31, 2025 | 313,297.00 |
| Dec 31, 2024 | 356,295.00 |
| Sep 30, 2024 | 657,000.00 |
| Jun 30, 2024 | 674,000.00 |
| Mar 31, 2024 | 691,000.00 |
| Dec 31, 2023 | 202,990.00 |
| Sep 30, 2023 | 694,000.00 |
| Jun 30, 2023 | 709,000.00 |
| Mar 31, 2023 | 724,000.00 |
| Dec 31, 2022 | 739,000.00 |
| Sep 30, 2022 | 5.05 Mn |
| Jun 30, 2022 | 2.69 Mn |
| Mar 31, 2022 | 2.71 Mn |
| Dec 31, 2021 | 2.72 Mn |
| Sep 30, 2021 | 2.24 Mn |
| Jun 30, 2021 | 1.75 Mn |